SCHEMBL4122892

SCHEMBL4122892

CCCc1ccc(NC(=O)Nc2ccc(C(=O)OC)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.64
ALDH1A1 P00352 1/20 0.64
MEN1 O00255 7/20 0.62
KMT2A Q03164 7/20 0.62
NPC1 O15118 5/20 0.62
RAB9A P51151 5/20 0.62
MAPK1 P28482 2/20 0.62
HTT P42858 2/20 0.62
KDM4E B2RXH2 2/20 0.62
CYP4A11 Q02928 2/20 0.55
LMNA P02545 1/20 0.55
HPGD P15428 1/20 0.55
CASP1 P29466 1/20 0.55
CYP4F2 P78329 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ABCG2 Q9UNQ0 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4609340 0.89 NPC1 (0.63) MEN1KMT2ANPC1RAB9AMAPK1
SCHEMBL4610276 0.89 NPC1 (0.63) MEN1KMT2ANPC1RAB9AMAPK1
SCHEMBL4124856 0.89 MAPT (0.70) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL1807631 0.88 CYP4A11 (0.68) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL4122842 0.88 KMT2A (0.69) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL4118275 0.88 MAPT (0.64) MAPTALDH1A1MEN1KMT2ANPC1
Ammonia Solution, Strong SCHEMBL9650075 0.87 CYP4A11 (0.66) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL15093809 0.87 HRH3 (0.65) MEN1KMT2ANPC1RAB9AABCG2
SCHEMBL4116745 0.86 RAB9A (0.67) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL4106216 0.85 RAB9A (0.67) MAPTMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MAPT 1654/4885ALDH1A1 994/4885MEN1 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.